The key to battling the COVID-19 pandemic and its potential aftermath is to develop a variety of vaccines that are efficacious and safe, elicit lasting immunity, and cover a range of SARS-CoV-2 variants. Recombinant viral receptor-binding domains (RBDs) are safe vaccine candidates but often have limited efficacy due to the lack of virus-like immunogen display pattern. Here we have developed a novel virus-like nanoparticle (VLP) vaccine that displays 120 copies of SARS-CoV-2 RBD on its surface. This VLP-RBD vaccine mimics virus-based vaccines in immunogen display, which boosts its efficacy, while maintaining the safety of protein-based subunit vaccines. Compared to the RBD vaccine, the VLP-RBD vaccine induced five times more neutralizing antibodies in mice that efficiently blocked SARS-CoV-2 from attaching to its host receptor and potently neutralized the cell entry of variant SARS-CoV-2 strains, SARS-CoV-1, and SARS-CoV-1-related bat coronavirus. These neutralizing immune responses induced by the VLP-RBD vaccine did not wane during the two-month study period. Furthermore, the VLP-RBD vaccine effectively protected mice from SARS-CoV-2 challenge, dramatically reducing the development of clinical signs and pathological changes in immunized mice. The VLP-RBD vaccine provides one potentially effective solution to controlling the spread of SARS-CoV-2. Author summary Both mRNA-based and viral vector-based vaccines are currently being distributed to curtail the COVID-19 pandemic. Continued development of more varieties of SARS-CoV-2 vaccines will help battle the many variants of SARS-CoV-2. Here we have developed a virus-like particle (VLP) vaccine that combines the effectiveness of virus-based vaccines and safety of protein-based vaccines. Using the lumazine synthase nanoparticle protein as the structural scaffold and 120 copies of SARS-CoV-2 receptor-binding domain as the surface immunogen, this VLP vaccine induced high-titer neutralizing antibody responses in mice that lasted >2 months and potently inhibited SARS-CoV-2, SARS-CoV-1, and their variants. The VLP vaccine also protected mice from high-titer SARS-CoV-2 challenge. The novel VLP vaccine may contribute to the protection of the human population from SARS-CoV-2 and its variants.
【초록키워드】 neutralizing antibody, SARS-CoV-2, Efficacy, Vaccine, coronavirus, immune response, Immunity, Neutralizing antibodies, COVID-19 pandemic, variant, SARS-CoV-2 vaccines, SARS-CoV-1, variants, SARS-CoV-2 vaccine, Spread, Protein, Viral, Receptor-binding domain, SARS-CoV-2 variants, mice, mRNA, immune responses, Effectiveness, vaccine candidate, Clinical signs, Neutralizing, Strains, Neutralizing antibody response, boost, VLP, Protein-based vaccines, recombinant, RBDs, subunit vaccines, Safe, SARS-CoV-2 RBD, the cell, human population, host receptor, domain, study period, cell entry, help, SARS-CoV-2 strains, immunized mice, pathological changes, Clinical sign, variants of SARS-CoV-2, FIVE, effective, neutralized, blocked, lack, develop, inhibited, provide, contribute, variety, reducing, elicit, the RBD, pathological change, curtail, mRNA-based, viral vector-based, 【제목키워드】 Vaccine, SARS-COV-2 infection, animal model, novel, PROTECT,